---

$7.20

+0.2960 ( +4.29% ) 1.1M

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-05	Sale	-50000.00	JOHNSON JOHN
2024-06-05	Sale	-50000.00	Schmid John P.
2024-06-05	Sale	-50000.00	BORMANN-KENNEDY BARBARA-JEAN ANNE
2024-06-05	Sale	-50000.00	Fairley Ricki Louise
2024-06-05	Sale	-50000.00	PERSKY MARLA
2024-06-05	Sale	-50000.00	SHERMAN JEFFREY W
2024-05-10	Buy	5400.00	Schmid John P.
2024-04-11	Sale	-6502.00	SHERMAN JEFFREY W
2024-04-01	Sale	-6474.00	Kong Garheng
2024-04-01	Sale	-89571.00	JOHNSON JOHN